BANGKOK, Thailand, Sept. 8 /PRNewswire/ -- Don Margolis, Chairman of The Repair Stem Cell Institute LLC (RSCI; http://www.RepairStemCells.org) based in Bangkok, Thailand told The Wall Street Transcript (TWST) in an exclusive news interview published today that future profits inside the stem cell research sector will be hard to come by over the next five years, even for companies specializing in Repair Stem Cells (often called "adult stem cells"), where new life science discoveries are coming faster than anybody can keep up with. TWST is an international financial news weekly published in New York City (http://www.twst.com). Highlights from the TWST news interview can be read by visiting the RSCI web site.
According to Mr. Margolis, stem cell research companies that store umbilical cord blood cells for future use will have "the best shot at making the first profits once the public becomes aware how well these stem cells work." The RSCI Chairman is the founder of TheraVitae, the first stem cell company in the world to successfully treat dying heart patients with Repair Stem Cells.
Among the other predictions Mr. Margolis made in this TWST financial news interview were the following:
-- Wall Street has been discounting Embryonic Stem Cell (ESC) company stocks from 2004 through this summer when these stocks hit new lows;
-- There are 2100 Adult Stem Cell clinical trials listed at
http://www.clinicaltrials.gov right now "for more diseases than I can count" said
Margolis, "and these clinical trials means two things: First, thousands and
thousands of human beings either have been treated, will be treated, or are
being treated in these clinical trials by the only stem cells with a chance
to improve their lives. Second, many powerful financial and investment
leaders are spending
|SOURCE Repair Stem Cell Institute LLC|
Copyright©2008 PR Newswire.
All rights reserved